BHPW
MYGN icon

Beverly Hills Private Wealth’s Myriad Genetics MYGN Stock Holding History

Beverly Hills Private Wealth’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,556
Closed -$103K – 346
2025
Q1 		$103K Buy
11,556
+327
+3% +$3.93K 0.02% 334
2024
Q4 		$154K Sell
11,229
-1,627
-13% -$30K 0.03% 326
2024
Q3 		$352K Sell
12,856
-2,791
-18% -$75.6K 0.07% 244
2024
Q2 		$383K Sell
15,647
-1,150
-7% -$25.2K 0.08% 229
2024
Q1 		$358K Sell
16,797
-804
-5% -$17.3K 0.08% 249
2023
Q4 		$337K Sell
17,601
-2,086
-11% -$36.1K 0.09% 236
2023
Q3 		$316K Sell
19,687
-19,648
-50% -$374K 0.09% 221
2023
Q2 		$760K Buy
39,335
+20,099
+104% +$439K 0.12% 178
2023
Q1 		$447K Buy
19,236
+3,631
+23% +$73.7K 0.14% 158
2022
Q4 		$226K Buy
+15,605
New +$291K 0.1% 204

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Beverly Hills Private Wealth's MYGN Position: Q2 2025 in Review

Beverly Hills Private Wealth sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 11,556 shares — an estimated $103K sold.

Beverly Hills Private Wealth first reported a position in MYGN in Q4 2022 and held it in 10 quarters. The position peaked at $760K in Q2 2023. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • Beverly Hills Private Wealth reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • Beverly Hills Private Wealth sold 11,556 Myriad Genetics shares in Q2 2025, an estimated $103K.
  • Beverly Hills Private Wealth first reported a position in Myriad Genetics in Q4 2022 and held it in 10 quarters.
  • Beverly Hills Private Wealth's Myriad Genetics position peaked at $760K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Beverly Hills Private Wealth's 13F filing for Q2 2025, filed 29 Jul 2025.